CN1829728A - 新颖化合物 - Google Patents

新颖化合物 Download PDF

Info

Publication number
CN1829728A
CN1829728A CNA2004800220063A CN200480022006A CN1829728A CN 1829728 A CN1829728 A CN 1829728A CN A2004800220063 A CNA2004800220063 A CN A2004800220063A CN 200480022006 A CN200480022006 A CN 200480022006A CN 1829728 A CN1829728 A CN 1829728A
Authority
CN
China
Prior art keywords
group
ring
mono
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800220063A
Other languages
English (en)
Chinese (zh)
Inventor
野村纯弘
坂本敏昭
植田喜一郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of CN1829728A publication Critical patent/CN1829728A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800220063A 2003-08-01 2004-07-30 新颖化合物 Pending CN1829728A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49152303P 2003-08-01 2003-08-01
US60/491,523 2003-08-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010105463425A Division CN102060888A (zh) 2003-08-01 2004-07-30 新颖化合物

Publications (1)

Publication Number Publication Date
CN1829728A true CN1829728A (zh) 2006-09-06

Family

ID=34115512

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800220063A Pending CN1829728A (zh) 2003-08-01 2004-07-30 新颖化合物
CN2010105463425A Pending CN102060888A (zh) 2003-08-01 2004-07-30 新颖化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010105463425A Pending CN102060888A (zh) 2003-08-01 2004-07-30 新颖化合物

Country Status (18)

Country Link
US (1) US7521430B2 (enExample)
EP (1) EP1654269B1 (enExample)
JP (1) JP4717811B2 (enExample)
KR (1) KR101101500B1 (enExample)
CN (2) CN1829728A (enExample)
AU (1) AU2004260760B2 (enExample)
BR (1) BRPI0413233A (enExample)
CA (1) CA2534022C (enExample)
EA (1) EA011025B1 (enExample)
ES (1) ES2527053T3 (enExample)
IL (1) IL173051A (enExample)
MX (1) MXPA06001273A (enExample)
NO (1) NO333679B1 (enExample)
NZ (1) NZ545305A (enExample)
TW (1) TWI377209B (enExample)
UA (5) UA86042C2 (enExample)
WO (1) WO2005012321A1 (enExample)
ZA (2) ZA200601686B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159561A (zh) * 2008-09-19 2011-08-17 诺瓦提斯公司 糖苷衍生物及其用途
CN103502245A (zh) * 2011-05-09 2014-01-08 詹森药业有限公司 (2s，3r，4r，5s，6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羟甲基)四氢-2h-吡喃-3，4，5-三醇的l-脯氨酸和柠檬酸共晶体
CN103896930A (zh) * 2014-04-02 2014-07-02 安徽联创药物化学有限公司 卡格列净半水合物药用晶型的制备方法
CN105008379A (zh) * 2013-02-26 2015-10-28 田边三菱制药株式会社 α-卤代四酰基葡萄糖的制造方法
CN105541814A (zh) * 2008-10-17 2016-05-04 詹森药业有限公司 制备可用作sglt抑制剂的化合物的方法

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100942622B1 (ko) * 2003-08-01 2010-02-17 미쓰비시 타나베 파마 코퍼레이션 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI365186B (en) 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
AU2007329490B2 (en) * 2006-12-04 2012-05-17 Janssen Pharmaceutica N.V. Thienyl-containing glycopyranosyl derivatives as antidiabetics
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
WO2009035969A1 (en) 2007-09-10 2009-03-19 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of sglt
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EP2668953A1 (en) 2008-05-22 2013-12-04 Bristol-Myers Squibb Company Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
WO2011047113A1 (en) * 2009-10-14 2011-04-21 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
WO2011051864A1 (en) 2009-11-02 2011-05-05 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
MY187718A (en) 2010-05-11 2021-10-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
CN103596944B (zh) 2011-04-13 2017-02-22 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
US9695159B2 (en) 2014-05-27 2017-07-04 Glenmark Pharmaceuticals Limited Process for preparation of canagliflozin
CN104045673B (zh) * 2014-06-06 2017-01-18 安徽省食品药品检验研究院 双‑三氮唑缀合的假二糖衍生物及其制备方法
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN106188022A (zh) * 2015-04-30 2016-12-07 上海医药工业研究院 伊格列净的制备方法
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
MA51203A (fr) 2017-11-30 2020-10-07 Idorsia Pharmaceuticals Ltd Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
MY210508A (en) 2018-07-19 2025-09-28 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1075626B (de) * 1960-02-18 Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
HUP0300057A3 (en) 2000-03-17 2003-09-29 Kissei Pharmaceutical Glucopyranosyloxy benzylbenzene derivatives, pharmaceutical compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
CN1293087C (zh) * 2000-09-29 2007-01-03 橘生药品工业株式会社 吡喃葡糖氧基苄基苯衍生物及其药物组合物
US7053060B2 (en) * 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
JP4035052B2 (ja) 2000-12-28 2008-01-16 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159561A (zh) * 2008-09-19 2011-08-17 诺瓦提斯公司 糖苷衍生物及其用途
CN105541814A (zh) * 2008-10-17 2016-05-04 詹森药业有限公司 制备可用作sglt抑制剂的化合物的方法
CN103502245A (zh) * 2011-05-09 2014-01-08 詹森药业有限公司 (2s，3r，4r，5s，6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羟甲基)四氢-2h-吡喃-3，4，5-三醇的l-脯氨酸和柠檬酸共晶体
CN103502245B (zh) * 2011-05-09 2016-10-26 詹森药业有限公司 (2s，3r，4r，5s，6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羟甲基)四氢-2h-吡喃-3，4，5-三醇的l-脯氨酸和柠檬酸共晶体
CN106317036A (zh) * 2011-05-09 2017-01-11 詹森药业有限公司 (2s,3r,4r,5s,6r)‑2‑(3‑((5‑(4‑氟苯基)噻吩‑2‑基)甲基)‑4‑甲基苯基)‑6‑(羟甲基)四氢‑2h‑吡喃‑3,4,5‑三醇的l‑脯氨酸和柠檬酸共晶体
CN106317036B (zh) * 2011-05-09 2019-10-11 詹森药业有限公司 一种化合物的柠檬酸共晶体
CN105008379A (zh) * 2013-02-26 2015-10-28 田边三菱制药株式会社 α-卤代四酰基葡萄糖的制造方法
CN105008379B (zh) * 2013-02-26 2018-06-29 田边三菱制药株式会社 α-卤代四酰基葡萄糖的制造方法
CN103896930A (zh) * 2014-04-02 2014-07-02 安徽联创药物化学有限公司 卡格列净半水合物药用晶型的制备方法
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法

Also Published As

Publication number Publication date
UA86042C2 (en) 2009-03-25
UA85569C2 (ru) 2009-02-10
ZA200601686B (en) 2007-05-30
US20070060545A1 (en) 2007-03-15
KR20060132539A (ko) 2006-12-21
KR101101500B1 (ko) 2012-01-03
EP1654269A1 (en) 2006-05-10
IL173051A (en) 2012-06-28
UA87991C2 (en) 2009-09-10
CA2534022C (en) 2012-10-02
NO20060219L (no) 2006-04-28
ZA200603880B (en) 2010-01-27
EP1654269B1 (en) 2014-10-15
CA2534022A1 (en) 2005-02-10
US7521430B2 (en) 2009-04-21
BRPI0413233A (pt) 2006-10-03
TWI377209B (en) 2012-11-21
JP4717811B2 (ja) 2011-07-06
IL173051A0 (en) 2006-06-11
NZ545305A (en) 2008-11-28
UA83377C2 (uk) 2008-07-10
WO2005012321A1 (en) 2005-02-10
EA200600348A1 (ru) 2006-08-25
CN102060888A (zh) 2011-05-18
NO333679B1 (no) 2013-08-05
JP2007518682A (ja) 2007-07-12
AU2004260760A1 (en) 2005-02-10
ES2527053T3 (es) 2015-01-20
TW200510440A (en) 2005-03-16
UA86599C2 (en) 2009-05-12
AU2004260760B2 (en) 2009-08-13
EA011025B1 (ru) 2008-12-30
MXPA06001273A (es) 2006-04-11

Similar Documents

Publication Publication Date Title
CN1829728A (zh) 新颖化合物
CN1189469C (zh) 作为抗菌剂的3－(杂芳基乙酰氨基)－2－氧化－氮杂环丁烷－1－磺酸衍生物
CN1177857C (zh) 吡喃葡萄糖氧基苄基苯衍生物、包含该物质的药用组合物及制备该衍生物用的中间体
KR101552187B1 (ko) Ｓｇｌｔ 억제제로서 유용한 화합물의 제조 방법
CN1293087C (zh) 吡喃葡糖氧基苄基苯衍生物及其药物组合物
CN102648196B (zh) 可用作sglt2的抑制剂的化合物的制备方法
JP6643773B2 (ja) 新規アルキレン誘導体
NO334706B1 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser av slike forbindelser, samt fremgangsmåter for fremstilling av nevnte forbindelser
HK1040708A1 (en) Aryl-substituted propanolamine derivatives, methods for their production, medicaments containing said compounds and their use
WO2023106310A1 (ja) Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体
CN1802154A (zh) 吡啶n－氧化物抗病毒药
JPWO2016031987A1 (ja) オートタキシン阻害活性を有するピリミジノン誘導体
CN117279898A (zh) 抗菌化合物
JP2010509216A (ja) ヘテロシクリル置換抗高コレステロール血症化合物
CN1942437A (zh) 作为环氧化酶－1－环氧化酶－2抑制剂的取代氮杂环丁烷化合物及其制备方法和作为药物的用途
CN1056369C (zh) 哒嗪酮衍生物或其盐和制备方法
CN1090185C (zh) 有双环氨基取代的吡啶酮羧酸衍生物,其酯及盐,以及可用作其中间体的双环类胺
CN1711250A (zh) 苯并噁吖辛因及其作为单胺再摄取抑制剂的用途
HK1082253B (en) Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them
HK1082253A1 (zh) 抗菌的吲哚酮恶唑烷酮、它们的制备中间体和含有它们的药物组合物
HK1061037B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060906